Maintenance Dose of Mounjaro (Tirzepatide)
The FDA-approved maintenance doses of tirzepatide (Mounjaro) for type 2 diabetes are 5 mg, 10 mg, or 15 mg administered subcutaneously once weekly, with 15 mg representing the maximum approved dose. 1
Dosing Initiation and Titration Schedule
Start all patients at 2.5 mg subcutaneously once weekly for the first 4 weeks; this starting dose is solely for treatment initiation and gastrointestinal tolerability—it is not intended to provide glycemic control. 1
After 4 weeks on 2.5 mg, increase to 5 mg once weekly; this represents the first maintenance dose that provides therapeutic glycemic benefit. 1
If additional glycemic control is needed after at least 4 weeks on the current dose, escalate by 2.5 mg increments (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg), maintaining each dose for a minimum of 4 weeks before further titration. 1
The 4-week titration interval is non-negotiable; accelerating dose escalation markedly increases gastrointestinal adverse events (nausea, vomiting, diarrhea) and treatment discontinuation rates. 2
Selecting the Optimal Maintenance Dose
For patients requiring moderate glycemic improvement (HbA1c reduction ~1.9–2.1%), maintain at 5 mg weekly; this dose produces mean weight loss of approximately 6–7 kg at 40–52 weeks. 1, 3
For patients requiring robust glycemic control (HbA1c reduction ~2.2%), escalate to 10 mg weekly; this dose achieves 19.5% mean body weight reduction at 72 weeks, with 50% of patients losing ≥20% of baseline weight. 2, 1
For patients with severe hyperglycemia or those requiring maximal weight loss (HbA1c reduction ~2.3–2.4%), titrate to 15 mg weekly; this dose produces 20.9–22.5% mean weight reduction at 72 weeks, with 57% achieving ≥20% loss and 40% achieving ≥25% loss. 2, 1, 4
Extended therapy beyond 72 weeks (up to 88 weeks) with 15 mg can achieve up to 26% total body weight reduction, demonstrating sustained long-term efficacy. 2
Comparative Efficacy by Dose
| Dose | Mean HbA1c Reduction | Mean Weight Loss (40–72 weeks) | % Achieving HbA1c <7% |
|---|---|---|---|
| 5 mg | -1.9 to -2.1% | 5–7 kg | 82–85% |
| 10 mg | -2.2% | 7.5–12 kg (19.5% of baseline) | 85–93% |
| 15 mg | -2.3 to -2.4% | 8.8–13 kg (20.9–22.5% of baseline) | 85–93% |
Administration Guidelines
Administer once weekly at any time of day, with or without meals; the day of weekly administration can be changed if at least 72 hours (3 days) separate consecutive doses. 1
Inject subcutaneously in the abdomen, thigh, or upper arm; rotate injection sites with each dose to minimize injection-site reactions. 1
If a dose is missed, administer as soon as possible within 4 days (96 hours); if more than 4 days have elapsed, skip the missed dose and resume the regular weekly schedule. 1
Re-initiation After Treatment Interruption
- If tirzepatide is discontinued for any duration, restart at 2.5 mg and repeat the full 4-week titration schedule before returning to the prior maintenance dose; failure to do so results in severe gastrointestinal intolerance. 2
Common Pitfalls to Avoid
Never skip the 2.5 mg starting dose—initiating at 5 mg or higher dramatically increases nausea, vomiting, and diarrhea, leading to treatment discontinuation. 2
Never accelerate titration faster than every 4 weeks—this raises adverse-event rates and compromises long-term adherence. 2
Do not combine tirzepatide with another GLP-1 receptor agonist; however, combination with SGLT2 inhibitors is safe and recommended for patients with cardiovascular or renal disease. 5
Reduce concurrent insulin doses by 20–30% and consider discontinuing sulfonylureas when initiating tirzepatide to prevent hypoglycemia. 2
Special Populations
In patients with type 2 diabetes, weight-loss efficacy is modestly reduced compared to those with obesity alone; the SURMOUNT-2 trial showed 12.8% (10 mg) and 14.7% (15 mg) weight reductions in diabetic patients versus 19.5–20.9% in non-diabetic obesity. 2
In advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²), tirzepatide requires no dose adjustment and is preferred over insulin due to lower hypoglycemia risk. 6
Tirzepatide is superior to semaglutide 1 mg for both glycemic control and weight loss, achieving 1.5–1.6% greater HbA1c reduction and 5–10 kg greater weight loss at comparable timepoints. 7, 8